Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
Cancer Research|January 21, 2006
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680Matthew A Young, Neil P Shah, Luke H Chao, et al.
American Journal of Hematology|February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyMichael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Nature Chemical Biology|March 4, 2014
Dual kinase-bromodomain inhibitors for rationally designed polypharmacologyPietro Ciceri, Susanne Müller, Alison O'Mahony, et al.
British Journal of Haematology|May 23, 2013
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studyNeil P Shah, Moshe Talpaz, Michael W N Deininger, et al.
Haematologica|February 25, 2021
The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatmentThai Hoa Tran, Jonathan V Nguyen, Adrian Stecula, et al.
British Journal of Haematology|May 29, 2023
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREENeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
The New England Journal of Medicine|June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasMoshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
Blood|December 7, 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Hagop M Kantarjian, Giuseppe Saglio, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Haematologica|February 9, 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibNeil P Shah, Dong-Wook Kim, Hagop Kantarjian, et al.
Cancer Research|January 21, 2006
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680Matthew A Young, Neil P Shah, Luke H Chao, et al.
American Journal of Hematology|February 5, 2010
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyMichael B Lilly, Oliver G Ottmann, Neil P Shah, et al.
Nature Chemical Biology|March 4, 2014
Dual kinase-bromodomain inhibitors for rationally designed polypharmacologyPietro Ciceri, Susanne Müller, Alison O'Mahony, et al.
British Journal of Haematology|May 23, 2013
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studyNeil P Shah, Moshe Talpaz, Michael W N Deininger, et al.
Haematologica|February 25, 2021
The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatmentThai Hoa Tran, Jonathan V Nguyen, Adrian Stecula, et al.
British Journal of Haematology|May 29, 2023
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREENeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
The New England Journal of Medicine|June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasMoshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
Blood|December 7, 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Hagop M Kantarjian, Giuseppe Saglio, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2014
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine Choy Smith, Elisabeth A Lasater, Kimberly C Lin, et al.
Pageof 12